Advertisement
Advertise with us
sidenav

Will Nicotine Be a Game Changer for COVID-19 Patients?

Advertisement
Advertise with us

Does nicotine protect users from contracting the coronavirus SARS-CoV-2, or reduce its impact once it’s in the body? These are serious questions—and highly controversial ones—and we may have solid answers soon.

A clinical trial is set to begin in France, providing nicotine patches to hospital staff and COVID-19 patients and measuring the results. The trial has the backing of celebrated Pasteur Institute neurobiologist Jean-Pierre Changeux, an expert on the cholinergic system (which includes the nicotinic receptors).

Because most COVID-19 patient data has measured the number of infected smokers, but has not identified smokeless tobacco or e-cigarette users, it’s possible that some other component in tobacco smoke is exerting a protective effect. But the interaction between nicotine and the receptors used for access to the organs by the coronavirus is the only hypothesis that has so far been advanced by researchers, and it seems the most probable.

Scientists have speculated about the potential protective effects of nicotine since the earliest coronavirus data from China showed that smokers were infected at far lower rates than the general public. We noted in a March 12 story that five studies from China showed that just 3.9-14.5 percent of diagnosed COVID-19 patients were listed as smokers, while the smoking rate for Chinese men is about 50 percent. That gulf has been seen again and again as data came in from other cohorts.

In late January, New Zealand pharmaceutical researcher and harm reduction advocate Eliana Golberstein Rubashkyn posed a possible mechanism by which nicotine could prevent the coronavirus from adhering to the receptors in the body’s cells that are its prime entry point. She posted her suggestion on Twitter.

In late March, cardiologist and e-cigarette researcher Konstantinos Farsalinos published a preliminary study that noted the low number of smokers in published data, and proposed a similar explanation. Nicotine might block the coronavirus from finding its target cells, Farsalinos said.

Since then, data from other countries—including the United States and France—have shown similar low rates of infection among smokers, and Farsalinos has updated his study with the new information. His hypothesis has evolved to also suggest that nicotine might modulate the “hyperinflammatory” reaction of the immune system (the so-called cytokine storm) that has been noted in some of the worst COVID-19 cases. If that's correct, nicotine might help prevent infection, and also reduce the damage caused in already infected patients.

Farsalinos calls for clinical trials with nicotine replacement therapies to test his hypothesis. The final journal publication of his paper—co-written with his University of West Attica (Greece) colleague Prof. Anastasia Barbouni and New York University Prof. Raymond Niaura—is due soon.

But Dr. Changeux and his French colleagues may have beaten the Farsalinos team to the punch—at least for purposes of fame and glory. Their paper, which wasn’t published in preliminary form until nearly a month after Farsalinos’ early version appeared, follows almost exactly the same methodology (applied to a group of French patients) and has essentially the same conclusions as the Farsalinos paper. Yet they don’t cite Farsalinos’ work.

Controversies in science are nothing new. Even theft of theories and outright plagiarism are not unheard of. But it would be a shame if Dr. Farsalinos, who has devoted so much of his life to research on nicotine and vaping, doesn’t get part of the public acclaim if nicotine indeed prevents deaths from COVID-19.

Whoever gets credit for the discovery may have to move mountains to convert the knowledge into widespread action. Tobacco control and public health interests will be lined up against any conclusion that nicotine could be beneficial to society as a whole. Anyone advocating preventive use of nicotine products—even those proven to be non-addictive, like patches—will be skewered and roasted alive by the industry that has spent the last 30 years turning the public perception of nicotine into something resembling a demonic plague.

Advertisement
Advertise with us
Latest Reviews
Article preview image
Freemax REXA PRO & REXA SMART Review: Too Smart?

The Freemax REXA PRO and REXA SMART are highly advanced pod vapes, offering seemingly endless features, beautiful touchscreens, and new DUOMAX pods.

Wed Jul 30 2025
Article preview image
OXVA XLIM Pro 2 DNA Review: A Match Made in Heaven!

The OXVA XLIM Pro 2 DNA is powered by a custom-made Evolv DNA chipset, offering a Replay function and dry hit protection. Read our review to find out more.

Fri Jul 18 2025
Article preview image
SKE Bar Review: A Reusable Crystal Bar!

The SKE Bar is a 2 mL replaceable pod vape with a 500 mAh battery, a 1.2-ohm mesh coil, and 35 flavors to choose from in 2% nicotine.

Mon Jul 7 2025
Advertisement
Advertise with us
Latest Learn
vaping taxes
Vaping Taxes in the United States and Around the World

Because of declining cigarette sales, state governments in the U.S. and countries around the world are looking to vapor products as a new source of tax revenue.

Thu Jul 31 2025
How Old Do You Have to Be to Vape?
How Old Do You Have to Be to Vape?

The legal age to buy e-cigarettes and other vaping products varies around the world. The United States recently changed the legal minimum sales age to 21.

Tue Jul 1 2025
Where vaping is banned or restricted
Vape Bans: E-Cigarette Restrictions in the U.S. and Worldwide

A list of vaping product flavor bans and online sales bans in the United States, and sales and possession bans in other countries.

Fri Jul 4 2025
About Authors
Jim McDonald
844 posts

Smokers created vaping for themselves without help from the tobacco industry or anti-tobacco crusaders, and I believe vapers and the vaping industry have the right to continue innovating to give everyone who wants to use nicotine access to safe and attractive non-combustible options. My goal is to provide clear, honest information about vaping and the challenges nicotine consumers face from lawmakers, regulators, and brokers of disinformation. You can find me on Twitter @whycherrywhy

See author’s profile
Vaping360.com strives to be the world's most trusted resource for vapers and smokers. We take pride in our editorial integrity, accuracy, and the honesty of our writers.
Read more about us

Rely on Our Expertise

At Vaping360, we take pride in our deep expertise and years of experience in the vaping industry. Our dedicated team of professionals is committed to leveraging their extensive knowledge to meet your needs and exceed your expectations.

Authenticity

Genuine insights backed by thorough and exhaustive research and testing.

Reliability

Consistent, accurate information from the vaping industry experts.

Empowerment

Transparent and reliable content for confident and informed decision-making.

About us

Our mission is clear: to help people who smoke transition to low-risk alternatives and contribute to a smoke-free world. With each article we publish and each review we conduct, we're working towards this goal.

about-us-banner
product preview